SAARAH ALKHAIRY: Open Payments
NPI 1104440361 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,091 in 51 payments from 10 companies in 2025. Trend: 2023 $1,564 · 2024 $873 · 2025 $2,091
Food & beverage: $2,091
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 21 | $526 |
| Teva Pharmaceuticals USA, Inc. | 5 | $419 |
| ABBVIE INC. | 3 | $267 |
| Neurocrine BioSciences, Inc. | 6 | $221 |
| Alkermes, Inc. | 9 | $171 |
| Janssen Pharmaceuticals, Inc | 2 | $146 |
| Axsome Therapeutics, Inc. | 1 | $143 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $31 |
Products named: COBENFY, UZEDY, VRAYLAR, INGREZZA, ARISTADA, Auvelity, CAPLYTA, SPRAVATO.
Industry payments across IL — which companies pay providers there.
